Scancell Holdings (SCLP) RNS Announcements

Add to Alert list
Date Time Source Announcement
10 May 2010 07:00 AM
PRN
Placing
05 May 2010 07:00 AM
PRN
CTA Approval for SCIB1
14 Apr 2010 07:00 AM
PRN
Placing of New Ordinary Shares
29 Mar 2010 07:00 AM
PRN
Results of Open Offer
10 Mar 2010 04:51 PM
PRN
Director/PDMR Shareholding
05 Mar 2010 10:22 AM
PRN
Open Offer
02 Feb 2010 07:00 AM
PRN
CTA for SCIB1 melanoma vaccine
29 Jan 2010 07:00 AM
PRN
Interim Results
24 Nov 2009 06:01 PM
PRN
Result of AGM
17 Nov 2009 07:00 AM
PRN
Appointment of PharmaNet
02 Nov 2009 07:00 AM
PRN
Completion of SCIB1 cGMP Manufacture
09 Sep 2009 07:00 AM
PRN
Final Results
06 Aug 2009 07:00 AM
PRN
Agreement with ImmunoVaccine Technologies
16 Jul 2009 07:00 AM
PRN
License of Ichor's TriGrid Electroporation Device
02 Jul 2009 07:00 AM
PRN
Merck Serono Licensing Agreement
01 Jul 2009 07:00 AM
PRN
Change of Advisor
26 Jan 2009 07:00 AM
PRN
Scancell Receives GBP250,000 emda Grant
22 Jan 2009 07:00 AM
PRN
GMP Manufacture Deal With Cobra
15 Jan 2009 07:00 AM
PRN
Half-yearly Report
19 Dec 2008 12:56 PM
Issue of Equity
20 Nov 2008 07:00 AM
PRN
Notice of Results
24 Sep 2008 07:01 AM
Audited Final Results for the Year Ended 30 Apr...
24 Sep 2008 07:00 AM
Admission and Start of Trading

Scancell Holdings PLC is a biopharmaceutical company that develops vaccines and other therapies to treat cancer and infectious diseases. Scancell's research focuses on the human immune system and how to use it to develop new treatments. Scancell uses four technology platforms to develop its products: ImmunoBody, Moditope, GlyMab and AvidiMab.

Scancell was founded in 1997 based on research led by Professor Lindy Durrant at the University of Nottingham.

Scancell Holdings PLC is listed on the London Stock Exchange (LSE) as SCLP.

Scancell share price listed at 8p in 2010.

UK 100

Latest directors dealings